Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wattana Karnpaet PCLBKK:NEW 79 3-1 Month Momentum % is -1.55% as of Sep. 01, 2026. GuruFocus rates BKK:NEW with a GF Score™ of 79/100 and a GF Value™ of ฿98.52 (Fairly Valued). The stock has 1 warning sign investors should review. Among 673 Healthcare Providers & Services companies, Wattana Karnpaet PCL ranks better than 50.07% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-01), Wattana Karnpaet PCL's 3-1 Month Momentum % is -1.55%.
The industry rank for Wattana Karnpaet PCL's 3-1 Month Momentum % or its related term are showing as below:
BKK:NEW's 3-1 Month Momentum % is ranked better than 50.07% of 673
companies
in the Healthcare Providers & Services industry
Industry Median: -1.55
vs BKK:NEW: -1.55
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Wattana Karnpaet PCL 3-1 Month Momentum % Related Terms
BKK:NEW vs HCA, THC, EHC: 3-1 Month Momentum % Comparison
For the Medical Care Facilities subindustry, Wattana Karnpaet PCL's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wattana Karnpaet PCL 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Wattana Karnpaet PCL's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Wattana Karnpaet PCL's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wattana Karnpaet PCL (BKK:NEW) has a 3-1 Month Momentum % of -1.55% as of Sep. 01, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Wattana Karnpaet PCL and its competitors. According to the industry distribution chart, Wattana Karnpaet PCL ranks #336 out of 673 companies in the Healthcare Providers & Services industry, placing it in the top 49.9%.
Is Wattana Karnpaet PCL's 3-1 Month Momentum % too high?
Wattana Karnpaet PCL's current 3-1 Month Momentum % is -1.55%. Based on the distribution chart, Wattana Karnpaet PCL ranks #336 out of 673 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Wattana Karnpaet PCL has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wattana Karnpaet PCL's 3-1 Month Momentum % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Wattana Karnpaet PCL ranks #336 out of 673 companies for 3-1 Month Momentum %. This puts Wattana Karnpaet PCL in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
A good 3-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Wattana Karnpaet PCL and its competitors. Wattana Karnpaet PCL's current 3-1 Month Momentum % is -1.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wattana Karnpaet PCL stock overvalued right now?
Based on GuruFocus' analysis, Wattana Karnpaet PCL (BKK:NEW) is currently considered Fairly Valued. The stock's GF Value™ is ฿98.52, compared to a current price of ฿92.75 — trading 5.9% below its estimated fair value. The current 3-1 Month Momentum % is -1.55%. Wattana Karnpaet PCL's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Wattana Karnpaet PCL (BKK:NEW), the current 3-1 Month Momentum % is -1.55% as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wattana Karnpaet PCL (BKK:NEW) Overvalued in 2026?
Based on GuruFocus' analysis, Wattana Karnpaet PCL stock appears to be undervalued.
The current stock price of ฿92.75 is trading 5.9% below its estimated GF Value™ of ฿98.52.
GuruFocus considers Wattana Karnpaet PCL to be Fairly Valued.
Key valuation signals for BKK:NEW:
3-1 Month Momentum %: -1.55%
GF Value™: ฿98.52 vs. price of ฿92.75 (5.9% below fair value)
No single metric tells the full story. See the BKK:NEW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wattana Karnpaet PCL is engaged in the operation of a hospital under the name North Eastern Wattana Hospital. It has a single segment of operation, namely the hospital and medical trading business. The company earns revenue from hospital, revenue from sales of medicines, and revenue from hospital rooms, which are derived from the provision of services to various types and a large number of customers. Geographically, the company's operations are carried out in Thailand.
79GF Score
Get the complete analysis for BKK:NEW
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:NEW has been successfully added to your 
